The goal of this study is to assess medical school students’ smoking rates, levels of addiction, factors influencing tobacco smoking, and attitudes toward tobacco information and bans.For this stud...

This study was conducted as a randomized controlled trial to investigate the effect of breathing exercises on fatigue in patients diagnosed with tuberculosis.

Background. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of cystic fibrosis (CF) patients in Türkiye is not known. In this study we aimed to determine the eligibility of CF patients in Türkiye for the CFTRms. Methods. The Cystic Fibrosis Registry of Türkiye (CFrT) data was used to determine the age of patients in the year 2021 and the genetic variants they were carrying. Age- and CFTR-variant appropriate modulator therapies were determined using the Vertex® algorithm. Results. Among a total of 1930 registered patients, CTFR gene analysis was performed on a total of 1841 (95.4%) patients. Mutations were detected in one allele in 10.7% (198 patients), and in both alleles in 79% (1455 patients) of patients. A total of 855 patients (51.7% for whom at least 1 mutation was detected) were eligible for the drugs. The most appropriate drug among genotyped patients was found to be elexacaftor/tezacaftor/ivacaftor for 486 patients (26.4%), followed by ivacaftor for 327 patients (17.7%) and lumacaftor/ivacaftor for 42 patients (2%). Conclusions. Only half of patients registered in CFrT were eligible for CFTRms, which is a significant difference from the CFTR variant profile seen in USA and Europe. However, access to treatment is hampered for some patients whose genes are not analysed. Further studies in CF populations, where rare mutations are relatively more common, will contribute to the field of CFTR modulator treatments for such rare mutations.

Objective: Muscle viscoelastic properties remain incompletely investigated in patients with chronic obstructive pulmonary disease (COPD). This study aimed to compare the viscoelastic properties of the accessory respiratory muscles and peripheral muscles between COPD patients and healthy individuals. Method: Sixty males were included in the study: patients with stable COPD and healthy adults (n=30 each). Pulmonary function was assessed using spirometry. Muscle viscoelastic properties, including tone (Hz), stiffness (N/m) and elasticity (E, inverse of logarithmic decrement), were quantified using MyotonPRO®. Result: Compared to the healthy group, the tone values of sternocleidomastoid muscles (SCM), left deltoid muscle (D), and left biceps brachii (BB) muscles were higher in the COPD group (bilateral SCMs; p < 0.001, left D; p = 0.014, left BB; p = 0.006). The stiffness values of SCMs (p < 0.001), as well as the left D (p = 0.008), and left BB muscles (p = 0.044) were also higher in the COPD group. The logarithmic decrements for the SCM, upper trapezius (UT), pectoralis major (PM), and D muscles bilaterally were higher in the COPD group (p = 0.031/p = 0.009; p < 0.01/p < 0.01; p = 0.006/p = 0.018; p = 0.005/p = 0.014, respectively, right/left side). Conclusion: Reduced elasticity of the respiratory muscles, particularly the SCM muscle, along with increased tone and stiffness, reflects a change in muscle viscoelastic properties in patients with COPD. Further studies are needed to assess the impact of COPD on the viscoelastic properties of lower extremity muscles.

Background/Objectives: The association between past coronavirus disease-19 (COVID-19) infection and pulmonary thromboembolism (PTE) is a potential research topic. We aimed to research the prevalence of previous COVID-19 infection in patients with PTE and to determine whether there is a difference in embolism severity in these cases. Methods: Study design: Multicenter, observational, cross-sectional. Patients diagnosed with PTE between 11 March 2022 and 11 March 2023 were prospectively included in this study, excluding cases with PTE along with active COVID-19, patients under the age of 18, and pregnant patients. Group 1 consisted of PTE cases with previous COVID-19, and Group 2 consisted of PTE cases without previous COVID-19. Key variables are D-Dimer level, right ventricle/left ventricle (RV/LV) ratio, simplified pulmonary embolism severity score, and treatment type. Results: A total of 1185 patients (Group 1; n = 360, Group 2; n = 825) were included in this study. The proportion of patients with RV/LV ratio > 1 on computed tomography pulmonary angiography (CTPA) was significantly high in Group 2 compared to Group 1 (27.9% vs. 19.7%, p = 0.003). In multivariate logistic regression analysis, the absence of any identifiable risk factor for PTE was found to be a 0.46-fold protective factor in the presence of previous COVID-19 (OR: 0.456 95% CI: 0.274–0.760, Wald = 9.070, df = 1, p = 0.003) and an RV/LV ratio > 1 on CTPA was found to be a 0.60-fold protective factor (OR: 0.603, 95% CI: 0.365–0.998, Wald = 3.874, df = 1, p = 0.049). Conclusions: The prevalence of previous COVID-19 infection in PTE cases was 30.4%, and 26.3% of idiopathic cases had previous COVID-19 infection. Although the parameters related to embolism severity were higher in the non-COVID-19 group, multivariate analyses revealed a 2.2-fold increased risk for idiopathic PTE and a 1.7-fold increased risk for RV/LV ratio > 1 on CTPA in patients without COVID-19 compared to those with prior COVID-19.

Objective: This study aimed to investigate the effects of difficulties experienced in the follow-up and treatment during the Coronavirus 2019 pandemic (COVID-19p), which included COVID-19 phobia and depression, on treatment compliance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: This study included 123 patients with COPD. The COVID-19 Phobia Scale (C19P-S), Beck Depression Inventory (BDI), and Medication Adherence Report Scale (MARS) were used to assess the patients. Results: The mean age of patients with COPD was 64.56 ± 9.31 years. It was determined that our patients did not maintain regular outpatient follow-up mostly because of the fear of COVID-19 transmission (78.8%). Overall, 24% of our patients showed treatment noncompliance. A statistically significant relationship was found between COPD stages B and D and treatment compliance (p=0.01). Patients with frequent emergency department admissions (p = 0.01) and those with high BDI (p = 0.01) and C19P-S (p = 0.02) scores during the pandemic were found to have reduced treatment compliance. Conclusion: Patients with COPD with COVID-19 phobia, and depression had reduced treatment compliance. İt is necessary to be aware of these conditions and to plan appropriate interventions.